NADH to treat:
Copy of Parkinsons Disease
Good news, 78% of the patients in a Parkinson’s Disease clinical study experienced positive improvements when taking an NADH supplement called ENADA / Co-E1. It is an NADH nutritional supplement that is a natural, energy-giving, co-enzyme found within every human cell. Since the mid-eighties, NADH has been used in Europe to successful treat more than 3,000 Parkinsonian patients. To validate these treatments, an open label clinical trial study was held with 885 Parkinsons’ Disease patients taking an daily 10mg NADH supplement (for the actual study results, see the link below). The clinical study findings validated that in 78% of the cases, patients taking NADH reported positive improvements in their condition.
In one of his latest seminars, Dr Birkmayer, (the Doctor that developed stabilized NADH in a oral tablet form,) stated that using a higher daily dose would have been better in the clinical trial. Dr Birkmayer recommended a Parkinson’s disease patient should take 40mg (or more) of NADH daily to experience 10% to 60% improvement in their condition. He said that they should see improvements in their condition in about two weeks. (See the one hour long video Dr. Birkmayer Teaches about NADH: The Good and the Bad)
The Clinical Testing:
Since the mid-eighties, NADH has been successfully used to treat more than 3,000 Parkinson's disease patients. These treatments were in Europe, and not in the US. A majority of the Parkinson’s disease patients experienced varying levels of positive improvements in their condition. To validate these results, an open label trial with 885 Parkinsion’s disease patients, were given 25mg of NADH daily. About half of the patients received NADH by intravenous means (a needle), and the other half received oral tablets. The patients that received the 25mg of NADH oral tablets experienced the best results. (The actual Parkinson's disease clinical study is available, see the link below.) The clinical study document is technical in nature, difficult to read, and is usually read by healthcare professionals. We recommend taking the study to your healthcare professional and discuss its results.
The study found there were three things that had significant influence on the improvement in condition. They are:
- the degree of the patient's disability before the treatment
- the duration of the disease within the patient before the treatment
- the age of the patient
In the simplest of terms, the younger patients, with a shorter duration of the disease, have a better chance to obtain the most significant improvements of Parkinson’s disease symptoms. The stages of the disease are important. If the Parkinson's disease is in the most advanced stages, it is very difficult to show improvement.
The clinical tests showed 78% of the patients taking NADH experienced varying levels of beneficial improvement. The percentages in improvement were:
- 19.3% of the patients showed a very good (30% to 50%) improvement
- 58.8% of the patients showed a moderate (10 - 30 %) improvement.
- 21.8 % of the patients did not respond to the NADH
NADH: A Background
The NADH Parkinson’s disease treatment comes from a coenzyme called NADH ornicotinamide adenine dinucleotide with the ‘H’ standing for hydrogen. What makes NADH promising is nature uses NADH to create mental and physical energy (called ATP) within all human cells. ATP energy creation takes place in a process called "cellular respiration." Cellular respiration is not breathing. Cellular respiration is like a cellular engine, creating energy used to power all living things (i.e., thought, memory, muscle movement, heart beats, etc.). Within the cellular respiration engine, all human cells bring glucose (fuel) and oxygen (air) together, and with the spark of NADH (spark plug) creates life's energy and power (ATP). ENADA / Co-E1 is an NADH nutritional supplement that has successfully reproduced the NADH co-enzyme in a stabilize form and is administered within a tablet. For more information about NADH in nature, take this website’s The Guided Tour.
Doctors that have tested NADH on patients have stated:
- NADH is a safe, natural compound that has shown much promise with patients in Europe.
- Much more extensive research is needed.
- A clinical trial for the treatment of Parkinson’s disease patients is a significant step, down a long road to investigate the many potential benefits of this natural coenzyme called NADH.
NADH is a coenzyme. The American Heritage Dictionary defines a coenzyme as:
- a non-protein organic substance that usually contains a vitamin or mineral and combines with a specific protein, to form an active enzyme system
NADH is not a drug, not a stimulant, and is non-toxic even in very large dosages (tested for 26 weeks at 1,000mg daily). Since NADH is already found within every human cell, NADH can safely be taken with any other medication. After extensive safety testing, it was proven NADH does not have any negative side effects and no adverse drug interactions. See this website’s section called Safety First for more information.
The most important things to remember about the NADH, which is found in every human cell, are:
- NADH increases the levels of cellular energy (ATP). The more NADH cells have -- the more ATP-energy cells produce. It increases cell longevity.
- NADH is a powerful antioxidant, a scavenger of free radicals. According to Dr. Passwater, "NADH may just be the most powerful antioxidant"
- NADH is the active ingredient in cellular repair and DNA repair
- NADH stimulates the immune system
- NADH enhances the production of dopamine, a very important brain chemical (a neurotransmitter)
- NADH increases the bio-availability of nitric oxide, known to provide increased blood flow, oxygen delivery, glucose uptake, muscle velocity, power output, and muscle growth
Parkinson’s disease: The Illness
Parkinson’s disease is a degenerative brain disorder initially characterized by trembling lips and hands, muscular rigidity and the slowing of movement. It develops gradually. As the disease progresses, it produces body tremors, a shuffling gait, and eventually a possible incapacity. Emotions may be affected. Mental capacity may be impaired. Depression often accompanies the disease. In the early stages of Parkinson's disease, the face may show little or no expression or the arms may not swing when you walk. Speech may become soft or slurred. Parkinson's disease symptoms worsen as the condition progresses over time.
The cause of Parkinson's disease is unknown, but several factors appear to play a role, including:
- The person’s Genes. Researchers have identified specific genetic mutations that can cause Parkinson's disease. These are uncommon except in rare cases when many family members are being affected by Parkinson's disease.
- Certain gene variations appear to increase the risk of Parkinson's disease but it is a relatively small risk for each of these genetic variations.
- Environmental triggers. Exposure to certain toxins, herbicides, pesticides and other environmental factors may increase the risk of Parkinson's disease, but the risk is relatively small.
- In summary, more research needs to be done to identify the factors that cause Parkinson's disease.
In Parkinson's disease, certain nerve cells (neurons) in the brain gradually break down or die. Many of the symptoms are due to loss of brain cells (neurons) that produce a chemical messenger (also known as neurotransmitters) in your brain called dopamine. When the brain cells that produce dopamine, stop producing dopamine, the dopamine levels decrease, and that causes abnormal brain activity, which leads to signs of Parkinson's disease. Parkinson’s disease is named for the English surgeon James Parkinson, who first described it in 1817.
Parkinson’s disease: Who Will Be Affected?
Who will be affected by Parkinson’s disease is unknown, but the following risks have been identified:
- Age. Young adults rarely experience Parkinson's disease. It ordinarily begins in middle or late life, and the risk increases with age. People usually develop the disease around age 60 or older
- Heredity. Having a close relative with Parkinson's disease increases the chances that you'll develop the disease. However, your risks are still small unless you have many relatives in your family with Parkinson's disease
- Sex. Men are more likely to develop Parkinson's disease than are women
- Exposure to toxins. Ongoing exposure to herbicides and pesticides may put a person at a slightly increased risk of Parkinson's disease
Parkinson’s disease: Diagnosis & Current Treatment:
It should be known that Dr. G. Birkmayer, the creator of the stabilized form of NADH which was administered to the 885 clinical study patients is the son of Dr. W Birkmayer, the doctor that invented the L-dopa therapy (in 1961) that is used as a therapy to treat Parkinson’s patients. It was the Birkmayer family that were the doctors that were successfully treating those 3,000 Parkinson patients in Europe (see the remarkable Parkinson Patient video below).
Although Parkinson's disease can't be cured, there are medications that are known to improve Parkinson’s disease symptoms. In occasional cases, the doctor may suggest surgery to regulate certain regions of your brain and improve the symptoms. Parkinson’s disease is treated with these drugs: sinemet, deprenyl (selegiline), L-DOPA (given with carbidopa to reduce side effects), amantadine and others. Parkinson's disease usually refers to similar symptoms resulting from certain anti-psychotic drugs (taken by the mentally ill), reserpine (a blood pressure medication), carbon monoxide poisoning, or MPTP (a byproduct of heroin usage).
It is the decreased levels of dopamine that causes abnormal brain activity, which leads to signs of Parkinson's disease. Dopamine is a monoamine neurotransmitter formed only in the brain by the decarboxylation of dopa. It is essential to the normal functioning of the central nervous system. A reduction in dopamine concentration within the brain is associated with Parkinson’s disease and Parkinsonism symptoms.
NADH is found within all human cells, and there are no drug interactions, nor any adverse side effects when taking an NADH supplement. Dr. W. Birkmayer is the doctor attributed to creating the L-dopa therapy used to treat Parkinson’s disease. Dr. Birkmayer ran the clinical trial of the 885 Parkinsonian patients taking an daily NADH supplement. During the study, Dr, Birkmayer recommended 25mg of NADH daily. In a recent seminar, Dr. Birkmayer increased his recommended dosage to 60mg of NADH daily to treat chronic diseases. (See the one hour long video "Dr. Birkmayer Teaches About NADH: The Good and the Bad"). NADH increases the levels of cellular energy (ATP); is a powerful antioxidant; is the active ingredient in cellular repair and DNA repair; stimulates the immune system; and most importantly NADH enhances the production of dopamine (and we know there are low levels of dopamine in a Parkinson’s disease patient).
The lack of physical or mental energy correlates with a lack of life’s energy called ATP. Every living cell produces ATP (also known as adenosine triphosphate) in a process called "cellular respiration." The human body uses ATP energy to enable the brain to provide: thinking, memory, mental clarity, etc. and enables muscles to provide: movement, stamina, physical endurance, etc. See this website’s section called ATP Energy for more information. Clinical studies have proven, the more NADH a cell has, the more ATP the cell will produce (see the link below). NADH is as important as oxygen and glucose (digested food) in the production of life’s energy (ATP). For more information about the production of NADH, take this website’s The Guided Tour.
The brain and the muscles need to contain high levels of NADH. If the cellular NADH levels are depleted, the brain or muscles will no longer function properly. How does NADH become depleted from the body? It is NOT known. Today, a scientific breakthrough has enabled NADH to be manufactured in a stabilized, tablet form. A person can restore NADH cellular levels by taking a nutritional supplement. High NADH levels, means higher levels of ATP (energy). The same NADH nutritional supplement used in the clinical study is available from this website or high quality nutritional supplement stores.
With knowledge it stands to reason, taking NADH could help some Parkinson’s disease sufferers. The clinical study states that it does not help everyone and it does not help with all symptoms. But helping 78% of the sufferers even a little is better than no help, or help with just treating the symptoms.
Take a copy of the clinical study to your healthcare professional and discuss the options. It yours to take.
Clinical Study Results:
NADH used to successfully treat 885 Parkinson’s Patients 78% experienced positive improvements in their condition
Parkinson's patients taking NADH (remarkable) positive effects [03:06]